PAVmed And TrueBlue On The List Of Winners And Losers Of Tuesday’s US Session

(VIANEWS) – Another day of trading has ended and here’s today‚Äôs list of stocks that have had significant trading activity in the US session.

The three biggest winners today are PAVmed, Ontrak, and Canopy Growth.

Rank Financial Asset Price Change Updated (EST)
1 PAVmed (PAVMW) 0.03 105.67% 2023-10-24 05:12:04
2 Ontrak (OTRKP) 0.30 42.86% 2023-10-24 03:49:05
3 Canopy Growth (CGC) 0.62 22.22% 2023-10-24 12:23:54
4 Personalis (PSNL) 1.08 16.12% 2023-10-24 13:09:06
5 Canaan (CAN) 1.93 12.87% 2023-10-24 12:16:17
6 MicroStrategy (MSTR) 423.96 12.31% 2023-10-24 12:13:57
7 Logitech (LOGI) 76.37 11.73% 2023-10-24 12:13:37
8 Marathon (MARA) 9.72 11.09% 2023-10-24 12:13:44
9 Quanterix Corporation (QTRX) 21.94 10.36% 2023-10-24 15:14:04
10 Aurora Cannabis (ACB) 0.47 9.98% 2023-10-24 13:01:03

The three biggest losers today are TrueBlue, Nkarta, and Nemaura Medical.

Rank Financial Asset Price Change Updated (EST)
1 TrueBlue (TBI) 10.29 -24.67% 2023-10-24 12:59:12
2 Nkarta (NKTX) 1.84 -16.59% 2023-10-23 21:09:06
3 Nemaura Medical (NMRD) 0.26 -15.42% 2023-10-23 21:11:05
4 Aspen Group (ASPU) 0.14 -9.74% 2023-10-24 12:16:04
5 Xerox Corporation (XRX) 12.35 -8.42% 2023-10-24 13:00:32
6 Fair Isaac Corproation (FICO) 850.05 -8.32% 2023-10-24 12:54:59
7 Phio Pharmaceuticals Corp. (PHIO) 1.28 -7.91% 2023-10-24 07:48:05
8 OpGen (OPGN) 0.70 -7.41% 2023-10-24 01:41:05
9 Equifax (EFX) 166.77 -6.85% 2023-10-24 12:20:23
10 Orgenesis (ORGS) 0.86 -5.87% 2023-10-24 03:10:05

Winners today

1. PAVmed (PAVMW) – 105.67%

NASDAQ ended the session with PAVmed rising 105.67% to $0.03 on Tuesday, after five consecutive sessions in a row of losses. NASDAQ jumped 0.93% to $13,139.88, following the last session’s upward trend on what was a somewhat up trend trading session today.

Volume

Today’s last reported volume for PAVmed is 32626 which is 397.12% above its average volume of 6563.

Moving Average

PAVmed’s worth is way under its 50-day moving average of $0.21 and way below its 200-day moving average of $1.66.

Yearly Top and Bottom Value

PAVmed’s stock is valued at $0.03 at 17:32 EST, way below its 52-week high of $4.74 and way higher than its 52-week low of $0.02.

More news about PAVmed.

2. Ontrak (OTRKP) – 42.86%

Ontrak, Inc. operates as an artificial intelligence powered, telehealth-enabled, and virtualized healthcare company that provides in-person services to third-party payors in the United States. Its technology-enabled platform predicts people whose chronic disease will improve with behavior change, recommends effective care pathways that people are willing to follow, and engages and guides them to and through the care they need. The company's technology enabled OnTrak program provides healthcare solutions to members with behavioral conditions that cause or exacerbate chronic medical conditions, such as diabetes, hypertension, coronary artery disease, chronic obstructive pulmonary disease, and congestive heart failure. The OnTrak integrates evidence-based psychosocial and medical interventions delivered in-person or via telehealth along with care coaching and in-market community care coordinators, who address the social and environmental determinants of health. The company was formerly known as Catasys, Inc. and changed its name to Ontrak, Inc. in July 2020. The company was incorporated in 2003 and is headquartered in Henderson, Nevada.

NASDAQ ended the session with Ontrak jumping 42.86% to $0.30 on Tuesday, following the last session’s upward trend. NASDAQ jumped 0.93% to $13,139.88, following the last session’s upward trend on what was a somewhat up trend exchanging session today.

Earnings Per Share

As for profitability, Ontrak has a trailing twelve months EPS of $-2.843.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -360.95%.

Revenue Growth

Year-on-year quarterly revenue growth declined by 24.2%, now sitting on 10.84M for the twelve trailing months.

Volume

Today’s last reported volume for Ontrak is 52146 which is 548.9% above its average volume of 8036.

Yearly Top and Bottom Value

Ontrak’s stock is valued at $0.30 at 17:32 EST, way below its 52-week high of $2.22 and way above its 52-week low of $0.05.

More news about Ontrak.

3. Canopy Growth (CGC) – 22.22%

Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in Canada, the United States, and Germany. It operates through two segments, Global Cannabis and Other Consumer Products. The company's products include dried cannabis flower, extracts and concentrates, beverages, gummies, and vapes. It offers its products under the Tweed, 7ACRES, 7ACRES Craft Collective, DOJA, Ace Valley, Quatreau, Deep Space, First + Free, Surity Pro, Spectrum Therapeutics, Vert, Tokyo Smoke, Twd, Martha Stewart CBD, DNA Genetics, BioSteel, Storz & Bickel, This Works, HiWay, Simple Stash, Whisl, and Truverra brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation was incorporated in 2009 and is headquartered in Smiths Falls, Canada.

NASDAQ ended the session with Canopy Growth jumping 22.22% to $0.62 on Tuesday, after five sequential sessions in a row of losses. NASDAQ jumped 0.93% to $13,139.88, following the last session’s upward trend on what was a somewhat bullish trend trading session today.

Earnings Per Share

As for profitability, Canopy Growth has a trailing twelve months EPS of $-1.38.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -99.56%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 2.6%, now sitting on 405.71M for the twelve trailing months.

Moving Average

Canopy Growth’s value is way under its 50-day moving average of $0.72 and way below its 200-day moving average of $1.28.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Canopy Growth’s stock is considered to be overbought (>=80).

Previous days news about Canopy Growth

  • Here's why canopy growth corporation (cgc) fell more than broader market. According to Zacks on Monday, 23 October, "The investment community will be paying close attention to the earnings performance of Canopy Growth Corporation in its upcoming release. ", "It is also important to note the recent changes to analyst estimates for Canopy Growth Corporation. "

More news about Canopy Growth.

4. Personalis (PSNL) – 16.12%

Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. It offers NeXT Platform, which provides data analysis for tumor and its immune microenvironment, from a single limited tissue or plasma sample; ImmunoID Next for tumor profiling from tissue; NeXT Liquid Biopsy for tumor profiling from plasma; NeXT Personal, a liquid biopsy offering for personalized tumor tracking for patients; NeXT Dx Test, a genomic cancer profiling test enabling composite biomarkers for cancer treatment; and NeXT SHERPA and NeXT NEOPS for neoantigen prediction capabilities. The company also provides ACE platform for clinical and therapeutic applications such as neoantigen prediction, biomarker identification, and novel drug target selection. It serves biopharmaceutical customers, universities, non-profits, and government entities. The company has partnership with Mayo Clinic; MapKure, LLC; SpringWorks Therapeutics, Inc.; and Moores Cancer Center. Personalis, Inc. was incorporated in 2011 and is headquartered in Menlo Park, California.

NASDAQ ended the session with Personalis rising 16.12% to $1.08 on Tuesday while NASDAQ rose 0.93% to $13,139.88.

Earnings Per Share

As for profitability, Personalis has a trailing twelve months EPS of $-2.36.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -50%.

Sales Growth

Personalis’s sales growth is 24.5% for the ongoing quarter and 8.4% for the next.

Yearly Top and Bottom Value

Personalis’s stock is valued at $1.08 at 17:32 EST, way below its 52-week high of $4.31 and way above its 52-week low of $0.91.

Growth Estimates Quarters

The company’s growth estimates for the current quarter and the next is 8.6% and 19.4%, respectively.

Volume

Today’s last reported volume for Personalis is 113853 which is 39.91% below its average volume of 189482.

More news about Personalis.

5. Canaan (CAN) – 12.87%

Canaan Inc. engages in the research, design, and sale of integrated circuit (IC) final mining equipment products by integrating IC products for bitcoin mining and related components in the People's Republic of China. It is also involved in the assembly and distribution of mining equipment and spare parts. The company has operations in the United States, Australia, Kazakhstan, Hong Kong, Canada, Mainland China, Thailand, Sweden, and internationally. Canaan Inc. was founded in 2013 and is based in Singapore.

NASDAQ ended the session with Canaan jumping 12.87% to $1.93 on Tuesday, following the last session’s upward trend. NASDAQ jumped 0.93% to $13,139.88, following the last session’s upward trend on what was a somewhat positive trend exchanging session today.

Earnings Per Share

As for profitability, Canaan has a trailing twelve months EPS of $-0.47.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -24.89%.

More news about Canaan.

6. MicroStrategy (MSTR) – 12.31%

MicroStrategy Incorporated provides enterprise analytics software and services in the United States, Canada, Europe, the Middle East, Africa, and internationally. It offers MicroStrategy, an enterprise analytics software platform that enables users to create visualizations, customize apps, and embed analytics directly into workflows; and MicroStrategy Cloud Environment, a managed software-as-a-service solution, which offers always-on threat monitoring and enables rapid analytics development and deployment to deliver security and data privacy requirements. The company also provides MicroStrategy Support that helps customers to achieve their system availability and uptime goals, and to improve the overall experience through highly responsive troubleshooting and proactive technical product support. In addition, it offers MicroStrategy Consulting, which offers customers with architecture and implementation services to help them quickly realize results, as well as helps to achieve returns on investment derived from understanding of data; and MicroStrategy Education that provides free and paid learning options, as well as holds and acquires bitcoin. The company offers its services through enterprise sales force and channel partners. It serves companies from a range of industries, including banking, technology, consulting, manufacturing, insurance, healthcare, and telecommunications, as well as the public sector. The company was incorporated in 1989 and is headquartered in Tysons Corner, Virginia.

NASDAQ ended the session with MicroStrategy rising 12.31% to $423.96 on Tuesday while NASDAQ rose 0.93% to $13,139.88.

Earnings Per Share

As for profitability, MicroStrategy has a trailing twelve months EPS of $9.36.

PE Ratio

MicroStrategy has a trailing twelve months price to earnings ratio of 45.29. Meaning, the purchaser of the share is investing $45.29 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 65.4%.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, MicroStrategy’s stock is considered to be oversold (<=20).

Revenue Growth

Year-on-year quarterly revenue growth declined by 1.4%, now sitting on 500.23M for the twelve trailing months.

Moving Average

MicroStrategy’s value is way above its 50-day moving average of $341.14 and way higher than its 200-day moving average of $311.49.

More news about MicroStrategy.

7. Logitech (LOGI) – 11.73%

Logitech International S.A., through its subsidiaries, designs, manufactures, and markets products that connect people to working, creating, gaming, and streaming worldwide. The company offers pointing devices, such as wireless mouse; corded and cordless keyboards, living room keyboards, and keyboard-and-mouse combinations; PC webcams; and keyboards for tablets and smartphones, as well as other accessories for mobile devices. It also provides keyboards, mice, headsets, and simulation products, such as gamepads, steering wheels, simulation controllers, console gaming headsets, and streamlabs services; video conferencing products, such as ConferenceCams, which combine enterprise-quality audio and high-definition video to bring video conferencing to businesses of any size; webcams and headsets that turn desktop into collaboration space; and controller for video conferencing room solutions. In addition, the company offers portable wireless Bluetooth and Wi-Fi connected speakers, mobile speakers, PC speakers, PC headsets, microphones, in-ear headphones, and wireless audio wearables. Its channel network includes consumer electronics distributors, retailers, e-tailers, computer and telecommunications stores, value-added resellers, and online merchants. The company sells its products under the Logitech, Logitech G, ASTRO Gaming, Streamlabs, Blue Microphones, and Ultimate Ears brands. Logitech International S.A. was incorporated in 1981 and is headquartered in Lausanne, Switzerland.

NASDAQ ended the session with Logitech jumping 11.73% to $76.37 on Tuesday, after five successive sessions in a row of losses. NASDAQ rose 0.93% to $13,139.88, following the last session’s upward trend on what was a somewhat positive trend trading session today.

Earnings Per Share

As for profitability, Logitech has a trailing twelve months EPS of $2.01.

PE Ratio

Logitech has a trailing twelve months price to earnings ratio of 38. Meaning, the purchaser of the share is investing $38 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 14.23%.

Volatility

Logitech’s last week, last month’s, and last quarter’s current intraday variation average was a negative 1.43%, a negative 0.13%, and a positive 1.19%.

Logitech’s highest amplitude of average volatility was 1.43% (last week), 1.18% (last month), and 1.19% (last quarter).

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Logitech’s stock is considered to be overbought (>=80).

Sales Growth

Logitech’s sales growth for the current quarter is negative 19%.

Dividend Yield

According to Morningstar, Inc., the next dividend payment is on Sep 24, 2023, the estimated forward annual dividend rate is 1.16 and the estimated forward annual dividend yield is 1.67%.

More news about Logitech.

8. Marathon (MARA) – 11.09%

Marathon Digital Holdings, Inc. operates as a digital asset technology company that mines digital assets with a focus on the blockchain ecosystem and the generation of digital assets in United States. The company was formerly known as Marathon Patent Group, Inc. and changed its name to Marathon Digital Holdings, Inc. in February 2021. Marathon Digital Holdings, Inc. was incorporated in 2010 and is headquartered in Fort Lauderdale, Florida.

NASDAQ ended the session with Marathon jumping 11.09% to $9.72 on Tuesday, after two consecutive sessions in a row of gains. NASDAQ jumped 0.93% to $13,139.88, following the last session’s upward trend on what was a somewhat bullish trend trading session today.

Earnings Per Share

As for profitability, Marathon has a trailing twelve months EPS of $-4.05.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -76.14%.

Volatility

Marathon’s last week, last month’s, and last quarter’s current intraday variation average was a negative 2.97%, a negative 0.61%, and a positive 4.41%.

Marathon’s highest amplitude of average volatility was 3.40% (last week), 4.03% (last month), and 4.41% (last quarter).

Earnings Before Interest, Taxes, Depreciation, and Amortization

Marathon’s EBITDA is 142.75.

Previous days news about Marathon

  • Marathon petroleum (mpc) registers a bigger fall than the market: important facts to note. According to Zacks on Monday, 23 October, "The upcoming earnings release of Marathon Petroleum will be of great interest to investors. ", "In terms of valuation, Marathon Petroleum is presently being traded at a Forward P/E ratio of 6.67. "
  • Marathon oil (mro) sees a more significant dip than broader market: some facts to know. According to Zacks on Monday, 23 October, "Its industry sports an average Forward P/E of 15.74, so one might conclude that Marathon Oil is trading at a discount comparatively.", "Valuation is also important, so investors should note that Marathon Oil has a Forward P/E ratio of 10.64 right now. "

More news about Marathon.

9. Quanterix Corporation (QTRX) – 10.36%

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. It offers HD-X instrument, a sensitive automated multiplex protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection technology in various applications, including direct detection of nucleic acids. The company also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assay kits and other consumables such as reagents. In addition, it offers contract research services, including sample testing, homebrew assay development, and custom development services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct sales force, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.

NASDAQ ended the session with Quanterix Corporation rising 10.36% to $21.94 on Tuesday while NASDAQ jumped 0.93% to $13,139.88.

Earnings Per Share

As for profitability, Quanterix Corporation has a trailing twelve months EPS of $-1.77.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -17.3%.

Yearly Top and Bottom Value

Quanterix Corporation’s stock is valued at $21.94 at 17:32 EST, way below its 52-week high of $28.77 and way above its 52-week low of $8.79.

Sales Growth

Quanterix Corporation’s sales growth is 3.5% for the ongoing quarter and 9% for the next.

More news about Quanterix Corporation.

10. Aurora Cannabis (ACB) – 9.98%

Aurora Cannabis Inc., together with its subsidiaries, produces, distributes, and sells cannabis and cannabis-derivative products in Canada and internationally. It operates through three segments: Canadian Cannabis, European Cannabis, and Plant Propagation. The company produces, distributes, and sells medical and consumer cannabis products in Canada. It is also involved in the distribution of wholesale medical cannabis in the European Union (EU); distribution of wholesale medical cannabis in various international markets, including Australia, the Caribbean, South America, and Israel; supply of propagated vegetables and ornamental plants in North America; and distribution and sale of hemp-derived cannabidiol (CBD) products. In addition, the company cultivates and sells dried cannabis, cannabis oils, capsules, edible cannabis, cannabis extracts, and soft gels, which are ingested in various ways, including smoking, vaporizing, and consumption in the form of oil, capsules, edibles, and extracts; and provides dried flowers, vapes, dried milled strains, strain-specific extracts, strain specific cannabis oils, and concentrates. Further, it offers recreational cannabis products, such as flowers, vapes, ingestibles, concentrates, extracts, and CBD products; and patient counseling and outreach services. The company's adult-use brand portfolio includes Aurora Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard, as well as CBD brands, Reliva and KG7; and medical cannabis brands include MedReleaf, CanniMed, Aurora, Whistler Medical Marijuana Co, Pedanios, Bidiol, and CraftPlant. Aurora Cannabis Inc. is headquartered in Leduc, Canada.

NYSE ended the session with Aurora Cannabis rising 9.98% to $0.47 on Tuesday while NYSE rose 0.53% to $15,025.76.

Earnings Per Share

As for profitability, Aurora Cannabis has a trailing twelve months EPS of $-5.77.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -102.67%.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Aurora Cannabis’s EBITDA is -27.79.

Yearly Top and Bottom Value

Aurora Cannabis’s stock is valued at $0.47 at 17:32 EST, way under its 52-week high of $1.62 and higher than its 52-week low of $0.43.

More news about Aurora Cannabis.

Losers Today

1. TrueBlue (TBI) – -24.67%

TrueBlue, Inc., together with its subsidiaries, provides specialized workforce solutions in the United States, Canada, the United Kingdom, Australia, and Puerto Rico. It operates through three segments: PeopleReady, PeopleManagement, and PeopleScout. The company's PeopleReady segment provides general, industrial, and skilled trade staffing services for construction, transportation, manufacturing, retail, hospitality, and renewable energy industries. Its PeopleManagement segment offers contingent, on-site industrial staffing, and commercial driver services, which includes on-site management and recruitment for the contingent industrial workforce of manufacturing, warehouse, and distribution facilities; and recruitment and management of contingent and dedicated commercial drivers to the transportation and distribution industries under the Staff Management, SIMOS Insourcing Solutions, and Centerline Drivers brands. The company's PeopleScout segment provides recruitment process outsourcing, talent advisory services, and managed service provider solutions including sourcing, screening, hiring, and onboarding services; operates Affinix, a technology platform which uses artificial intelligence and machine learning for real-time insights; and contingent labor programs including vendor selection, performance management, compliance monitoring, and risk management. TrueBlue, Inc. was formerly known as Labor Ready, Inc. and changed its name to TrueBlue, Inc. in December 2007. The company is headquartered in Tacoma, Washington.

NYSE ended the session with TrueBlue falling 24.67% to $10.29 on Tuesday while NYSE rose 0.53% to $15,025.76.

Earnings Per Share

As for profitability, TrueBlue has a trailing twelve months EPS of $0.47.

PE Ratio

TrueBlue has a trailing twelve months price to earnings ratio of 21.89. Meaning, the purchaser of the share is investing $21.89 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 3.51%.

Revenue Growth

Year-on-year quarterly revenue growth declined by 16.5%, now sitting on 2.07B for the twelve trailing months.

Volatility

TrueBlue’s last week, last month’s, and last quarter’s current intraday variation average was a negative 1.97%, a negative 0.17%, and a positive 1.72%.

TrueBlue’s highest amplitude of average volatility was 1.97% (last week), 1.27% (last month), and 1.72% (last quarter).

Growth Estimates Quarters

The company’s growth estimates for the ongoing quarter and the next is a negative 69.3% and a negative 53.5%, respectively.

More news about TrueBlue.

2. Nkarta (NKTX) – -16.59%

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a lymphocyte that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, that is in phase I for the treatment of various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

NASDAQ ended the session with Nkarta sliding 16.59% to $1.84 on Tuesday, after four sequential sessions in a row of losses. NASDAQ rose 0.93% to $13,139.88, following the last session’s upward trend on what was a somewhat bullish trend exchanging session today.

Earnings Per Share

As for profitability, Nkarta has a trailing twelve months EPS of $-2.54.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -33.84%.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Nkarta’s EBITDA is 3.47.

Volume

Today’s last reported volume for Nkarta is 2455350 which is 5.69% above its average volume of 2322970.

Moving Average

Nkarta’s worth is above its 50-day moving average of $1.75 and way under its 200-day moving average of $3.50.

More news about Nkarta.

3. Nemaura Medical (NMRD) – -15.42%

Nemaura Medical Inc., a medical technology company, manufactures continuous glucose monitoring system in the United States. It offers sugarBEAT, a non-invasive continuous glucose monitoring device for use by persons with Type I and Type II diabetes, as well as screen pre-diabetic patients. The company also offers proBEAT, a wellness guidance notes, that provide prompts and educate users on factors affecting blood sugar profiles, as well as conducts diabetes prevention and reversal programs. Nemaura Medical Inc. was founded in 2009 and is based in New York, New York.

NASDAQ ended the session with Nemaura Medical sliding 15.42% to $0.26 on Tuesday, following the last session’s downward trend. NASDAQ jumped 0.93% to $13,139.88, following the last session’s upward trend on what was a somewhat positive trend trading session today.

Earnings Per Share

As for profitability, Nemaura Medical has a trailing twelve months EPS of $-0.5.

Yearly Top and Bottom Value

Nemaura Medical’s stock is valued at $0.26 at 17:32 EST, way below its 52-week high of $3.43 and above its 52-week low of $0.25.

Volume

Today’s last reported volume for Nemaura Medical is 130454 which is 44.25% below its average volume of 233998.

More news about Nemaura Medical.

4. Aspen Group (ASPU) – -9.74%

Aspen Group, Inc., an education technology company, provides online higher education services in the United States. The company offers baccalaureate, master's, and doctoral degree programs in nursing and health sciences, business and technology, arts and sciences, and education fields through Aspen University and United States University. As of April 30, 2022, it had 13,334 degree-seeking students enrolled. Aspen Group, Inc. was founded in 1987 and is based in New York, New York.

NASDAQ ended the session with Aspen Group sliding 9.74% to $0.14 on Tuesday while NASDAQ rose 0.93% to $13,139.88.

Earnings Per Share

As for profitability, Aspen Group has a trailing twelve months EPS of $-0.38.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -24.26%.

Revenue Growth

Year-on-year quarterly revenue growth declined by 22.5%, now sitting on 70.92M for the twelve trailing months.

Moving Average

Aspen Group’s value is under its 50-day moving average of $0.15 and way under its 200-day moving average of $0.16.

Yearly Top and Bottom Value

Aspen Group’s stock is valued at $0.14 at 17:32 EST, way under its 52-week high of $0.55 and way above its 52-week low of $0.03.

Volume

Today’s last reported volume for Aspen Group is 15966 which is 45.84% below its average volume of 29484.

More news about Aspen Group.

5. Xerox Corporation (XRX) – -8.42%

Xerox Holdings Corporation, a workplace technology company, designs, develops, and sells document management systems and solutions in the Americas, Europe, the Middle East, Africa, India, and internationally. It offers workplace solutions, including desktop monochrome, and color and multifunction printers; digital printing presses and light production devices, and solutions; and digital services that leverage workflow automation, personalization and communication software, content management solutions, and digitization services. The company also provides graphic communications and production solutions; and IT services, end user computing devices, network infrastructure, communications technology, and a range of managed IT solutions, such as technology product support, professional engineering, and commercial robotic process automation; and provides finance for the sale of Xerox, non-Xerox office, and IT services equipment. In addition, it provides FreeFlow a portfolio of software solutions for the automation and integration to the processing of print job comprises file preparation, final production, and electronic publishing. Further, the company sells paper products and wide-format systems, licensing, as well as standalone software such as CareAR, DocuShare, and XMPie. The company sells its products and services directly to its customers through its direct sales force, as well as through independent agents, dealers, value-added resellers, systems integrators, and e-commerce marketplaces. Xerox Holdings Corporation was founded in 1906 and is headquartered in Norwalk, Connecticut.

NYSE ended the session with Xerox Corporation dropping 8.42% to $12.35 on Tuesday while NYSE rose 0.53% to $15,025.76.

Earnings Per Share

As for profitability, Xerox Corporation has a trailing twelve months EPS of $-1.7.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -6.45%.

Dividend Yield

As claimed by Morningstar, Inc., the next dividend payment is on Dec 27, 2023, the estimated forward annual dividend rate is 1 and the estimated forward annual dividend yield is 7.28%.

Volume

Today’s last reported volume for Xerox Corporation is 4147820 which is 134.75% above its average volume of 1766900.

Volatility

Xerox Corporation’s last week, last month’s, and last quarter’s current intraday variation average was a negative 2.00%, a negative 0.72%, and a positive 1.40%.

Xerox Corporation’s highest amplitude of average volatility was 2.00% (last week), 1.21% (last month), and 1.40% (last quarter).

More news about Xerox Corporation.

6. Fair Isaac Corproation (FICO) – -8.32%

Fair Isaac Corporation develops analytic, software, and data decisioning technologies and services that enable businesses to automate, enhance, and connect decisions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates through two segments, Scores and Software. The Software segment provides pre-configured analytic and decision management solution designed for various business needs or processes, such as account origination, customer management, customer engagement, fraud detection, financial crimes compliance, and marketing, as well as associated professional services. This segment also offers FICO Platform, a modular software offering designed to support advanced analytic and decision use cases, as well as stand-alone analytic and decisioning software that can be configured by customers to address a wide range of business use cases. The Scores segment provides business-to-business scoring solutions and services for consumers that give clients access to predictive credit and other scores that can be integrated into their transaction streams and decision-making processes, as well as business-to-consumer scoring solutions comprising myFICO.com subscription offerings. Fair Isaac Corporation markets its products and services primarily through its direct sales organization and indirect channels, as well as online. The company was formerly known as Fair Isaac & Company, Inc. and changed its name to Fair Isaac Corporation in July 1992. Fair Isaac Corporation was founded in 1956 and is headquartered in Bozeman, Montana.

NYSE ended the session with Fair Isaac Corproation falling 8.32% to $850.05 on Tuesday while NYSE jumped 0.53% to $15,025.76.

Earnings Per Share

As for profitability, Fair Isaac Corproation has a trailing twelve months EPS of $16.5.

PE Ratio

Fair Isaac Corproation has a trailing twelve months price to earnings ratio of 51.52. Meaning, the purchaser of the share is investing $51.52 for every dollar of annual earnings.

More news about Fair Isaac Corproation.

7. Phio Pharmaceuticals Corp. (PHIO) – -7.91%

Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on targeting tumor and immune cells by regulating genes of the immune system. The company develops PH-762 that activates immune cells to recognize and kill cancer cells by reducing the expression of the checkpoint protein PD-1 for immunotherapy in adoptive cell transfer (ACT); PH-894 that silences the epigenetic protein BRD4, which is an intracellular regulator of gene expression for use in ACT; and PH-804 that targets the suppressive immune receptor TIGIT, which is a checkpoint protein present on T cells and natural killer cells for use in ACT. It has collaborations with AgonOx Inc. on clinical development of novel T cell-based cancer immunotherapies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.

NASDAQ ended the session with Phio Pharmaceuticals Corp. dropping 7.91% to $1.28 on Tuesday, following the last session’s downward trend. NASDAQ jumped 0.93% to $13,139.88, following the last session’s upward trend on what was a somewhat positive trend exchanging session today.

Earnings Per Share

As for profitability, Phio Pharmaceuticals Corp. has a trailing twelve months EPS of $-9.82.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -92.6%.

Moving Average

Phio Pharmaceuticals Corp.’s value is way below its 50-day moving average of $1.85 and way under its 200-day moving average of $3.82.

Yearly Top and Bottom Value

Phio Pharmaceuticals Corp.’s stock is valued at $1.28 at 17:32 EST, way below its 52-week high of $12.27 and higher than its 52-week low of $1.26.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Phio Pharmaceuticals Corp.’s EBITDA is 1.28.

More news about Phio Pharmaceuticals Corp..

8. OpGen (OPGN) – -7.41%

OpGen, Inc., a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits. The company's products also comprise ARES Technology Platform, including ARES reference database on antimicrobial resistance using next generation sequencing technology and artificial intelligence powered bioinformatics solutions for antibiotic response prediction; and Unyvero Platform, an automated sample-to-answer molecular diagnostics platform that integrates automated sample preparation, analysis, and identification of disease relevant pathogens and antibiotic resistance markers. It also utilizes molecular diagnostics and informatics to help combat infectious diseases. The company helps clinicians with information about life threatening infections to enhance patient outcomes, and to decrease the spread of infections caused by multidrug-resistant microorganisms. OpGen, Inc. has a collaboration with the New York State Department of Health and ILÚM Health Solutions, LLC to develop a research program to detect, track, and manage antimicrobial-resistant infections at healthcare institutions. The company was incorporated in 2001 and is headquartered in Rockville, Maryland.

NASDAQ ended the session with OpGen falling 7.41% to $0.70 on Tuesday while NASDAQ rose 0.93% to $13,139.88.

Earnings Per Share

As for profitability, OpGen has a trailing twelve months EPS of $-11.97.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -211.58%.

More news about OpGen.

9. Equifax (EFX) – -6.85%

Equifax Inc. operates as a data, analytics, and technology company. The company operates through three segments: Workforce Solutions, U.S. Information Solutions (USIS), and International. The Workforce Solutions segment offers services that enables customers to verify income, employment, educational history, criminal justice data, healthcare professional licensure, and sanctions of people in the United States; and employer customers with services that assist them in complying with and automating payroll-related and human resource management processes throughout the entire cycle of the employment relationship. The USIS segment provides consumer and commercial information services, such as credit information and credit scoring, credit modeling and portfolio analytics, locate, fraud detection and prevention, identity verification, and other consulting services; mortgage services; financial marketing services; identity management services; and credit monitoring products. The International segment offers information service products, which include consumer and commercial services, such as credit and financial information, and credit scoring and modeling; and credit and other marketing products and services, as well as offers information, technology, and other services to support debt collections and recovery management. The company serves customers in financial services, mortgage, retail, telecommunications, utilities, automotive, brokerage, healthcare, and insurance industries, as well as government agencies. It operates in the United States, Canada, Australia, New Zealand, India, the United Kingdom, Spain, Portugal, Argentina, Chile, Costa Rica, Dominican Republic, Ecuador, El Salvador, Honduras, Mexico, Paraguay, Peru, Uruguay, and the Republic of Ireland. The company was founded in 1899 and is headquartered in Atlanta, Georgia.

NYSE ended the session with Equifax sliding 6.85% to $166.77 on Tuesday, following the last session’s upward trend. NYSE rose 0.53% to $15,025.76, after four successive sessions in a row of losses, on what was a somewhat bullish trend exchanging session today.

Earnings Per Share

As for profitability, Equifax has a trailing twelve months EPS of $4.33.

PE Ratio

Equifax has a trailing twelve months price to earnings ratio of 38.52. Meaning, the purchaser of the share is investing $38.52 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.74%.

Growth Estimates Quarters

The company’s growth estimates for the present quarter and the next is 25% and 30.8%, respectively.

More news about Equifax.

10. Orgenesis (ORGS) – -5.87%

Orgenesis Inc., a biotech company, focusing on cell and gene therapies worldwide. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed POCare therapeutics that are processed and produced in closed automated POCare technology systems across a collaborative POCare network. It focuses on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient at their point of care for treatment of the patient. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is based in Germantown, Maryland.

NASDAQ ended the session with Orgenesis dropping 5.87% to $0.86 on Tuesday while NASDAQ jumped 0.93% to $13,139.88.

Earnings Per Share

As for profitability, Orgenesis has a trailing twelve months EPS of $-0.51.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -37.99%.

Growth Estimates Quarters

The company’s growth estimates for the ongoing quarter and the next is 300% and 212.5%, respectively.

More news about Orgenesis.

Stay up to date with our winners and losers daily report

Leave a Reply

Your email address will not be published. Required fields are marked *